Get the Stockscreener App
1.04
12.61%
-0.15
Vaccinex Inc stock is traded at $1.04, with a volume of 371.
It is down -12.61% in the last 24 hours and down -69.06% over the past month.
See More
Previous Close:
$1.19
Open:
$1.04
24h Volume:
371
Relative Volume:
1.50
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-22.01M
P/E Ratio:
-0.0122
EPS:
-85.4
Net Cash Flow:
$-18.31M
1W Performance:
-12.61%
1M Performance:
-69.06%
6M Performance:
-81.55%
1Y Performance:
-88.61%
1-Day Range:
$1.04
$1.04
1-Week Range:
$1.04
$1.04
52-Week Range:
$1.04
$1.25
Vaccinex Inc Stock (VCNX) Company Profile
Compare VCNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCNX
Vaccinex Inc
|
1.04 | 0 | 0 | -22.01M | -18.31M | -85.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.00 | 117.23B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
668.32 | 72.75B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
645.61 | 38.65B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.79 | 34.69B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.69 | 27.45B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vaccinex Inc Stock (VCNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-04-18 | Initiated | Ladenburg Thalmann | Buy |
Vaccinex Inc Stock (VCNX) Latest News
Vaccinex (OTC:VCNX) Stock Quotes, Forecast and News Summary - Benzinga
Vaccinex (NASDAQ:VCNX) Stock Price Down 3.4% – What’s Next? - Defense World
Vaccinex Stock to Be Delisted From Nasdaq - Marketscreener.com
Vaccinex Faces Delisting from Nasdaq, Details Plans for OTC Quotation - Defense World
Vaccinex to be delisted from Nasdaq over equity shortfall By Investing.com - Investing.com South Africa
Vaccinex receives delisting notice from Nasdaq, shares down over 49% - MSN
Vaccinex to be delisted from Nasdaq over equity shortfall - Investing.com India
Vaccinex Shares Tumble 63% On Nasdaq Delisting - MarketWatch
Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62% - Yahoo Finance
Vaccinex stock plunges to 52-week low at $1.36 amid market challenges - Investing.com
Vaccinex Announces Receipt of Delisting Notification from Nasdaq - The Manila Times
Vaccinex Faces Nasdaq Delisting After Failing Minimum Equity Requirements, Moves to OTC Markets - StockTitan
Dow Dips Over 200 Points; US Retail Sales Top Estimates - Benzinga
Vaccinex, Inc. (NASDAQ:VCNX) Sees Large Decline in Short Interest - Defense World
Vaccinex (NASDAQ:VCNX) Trading 11.1% Higher – Time to Buy? - Defense World
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Vaccinex Reports Promising Alzheimer's Drug Data, Raises $8.35M Amid Financial Challenges | VCNX Stock News - StockTitan
Vaccinex secures $2.15 million in private placement - Investing.com
Vaccinex Inc (VCNX) Quarterly 10-Q Report - Quartzy
Vaccinex secures $2.15 million in private placement By Investing.com - Investing.com UK
SIMM Launches WNY Stock Index - The Bona Venture
ARMISTICE CAPITAL, LLC Acquires Shares in Vaccinex Inc - GuruFocus.com
Vaccinex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Latest Company News - Investing.com
Vaccinex inks multiple antibody discovery deals using ActivMAb By Investing.com - Investing.com Canada
Vaccinex inks multiple antibody discovery deals using ActivMAb - Investing.com India
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC - GlobeNewswire
Vaccinex Lands Major Pharma Deals: Amgen, Merck Partner on Breakthrough Antibody Tech | VCNX Stock News - StockTitan
Vaccinex Reports Improved Immunity Correlating with - GlobeNewswire
VCNXVaccinex, Inc. Latest Stock News & Market Updates - StockTitan
Vaccinex's Pepinemab Breakthrough: New Data Shows Enhanced Cancer Immunotherapy Success | VCNX Stock News - StockTitan
Vaccinex reports progress in Alzheimer's treatment study By Investing.com - Investing.com Canada
Vaccinex reports progress in Alzheimer's treatment study - Investing.com India
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 - GlobeNewswire
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain - Nasdaq
Capricor Therapeutics (CAPR) Faces 5% Drop Amid Industry Slump - GuruFocus.com
Vaccinex stock tanks 40% despite positive Alzheimer’s study update - MSN
Vaccinex Stock Spikes On 'Promising' Data On Alzheimer’s Drug Study: Retail Sentiment Brightens - Barchart
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024 - GlobeNewswire
Micron Technology (MU-Q) QuotePress Release - The Globe and Mail
Orange Juice (OJX25) Quote - The Globe and Mail
Antibody Library Technology Market Report to 2032 -AnaptysBio Inc, MorphoSys AG, XOMA Corporation, Abzena Plc, AvantGen – IndiaPolitics.com - IndiaPolitics.com
Vaccinex faces potential Nasdaq delisting over equity shortfall - Investing.com India
BTIG Research’s latest rating for VCNX stock - Knox Daily
Vaccinex faces potential Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
Vaccinex Inc Stock (VCNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.54%
8.70%
Cap:
|
Volume (24h):